Extracellular Vesicle-Associated Tissue Factor Activity in Prostate Cancer Patients with Disseminated Intravascular Coagulation

被引:20
作者
Hell, Lena [1 ]
Daeullary, Thomas [1 ]
Burghart, Vanessa [1 ]
Mauracher, Lisa-Marie [1 ]
Grilz, Ella [1 ]
Moser, Bernhard [2 ]
Kramer, Gero [3 ]
Schmid, Johannes A. [2 ]
Ay, Cihan [1 ]
Pabinger, Ingrid [1 ]
Thaler, Johannes [1 ]
机构
[1] Med Univ Vienna, Clin Div Haematol & Haemostaseol, Dept Med 1, A-1090 Vienna, Austria
[2] Med Univ Vienna, Inst Physiol, Ctr Physiol & Pharmacol, A-1090 Vienna, Austria
[3] Med Univ Vienna, Dept Urol, A-1090 Vienna, Austria
基金
奥地利科学基金会;
关键词
prostate cancer; disseminated intravascular coagulation; tissue factor; extracellular vesicles; peripheral blood mononuclear cells; platelets;
D O I
10.3390/cancers13071487
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary Disseminated intravascular coagulation (DIC) may occur in patients with advanced prostate cancer. In the present study, we detected elevated extracellular vesicle (EV)-associated tissue factor (TF) activity in the plasma of prostate cancer patients with DIC compared with matched prostate cancer patients without DIC and healthy individuals. TF-exposing EVs from DIC patients were highly coagulant in a clotting assay. In in vitro co-culture experiments, EV-TF activity was increased by interactions between a TF-exposing prostate cancer cell line (DU145), peripheral blood mononuclear cells (PBMCs), and platelets. Data from this study contribute to the understanding of the pathogenesis of prostate cancer-related DIC. Patients with advanced prostate cancer may develop fulminant disseminated intravascular coagulation (DIC). Circulating extracellular vesicles (EVs)-exposing tissue factor (TF), the initiator of the coagulation cascade, may play an important role. We included 7 prostate cancer patients with DIC, 10 age- and stage-matched cancer controls without DIC, and 10 age-matched healthy male individuals. EV-TF activity was highly elevated in prostate cancer patients with DIC (11.40 pg/mL; range: 4.34-27.06) compared with prostate cancer patients without DIC (0.09 pg/mL; range: 0.00-0.30, p = 0.001) and healthy controls (0.18 pg/mL; range: 0.09-0.54; p = 0.001). Only EVs from patients with DIC reduced fibrin clot formation time of pooled plasma in a TF-dependent manner. Next, we performed in vitro co-culture experiments including EVs derived from a prostate cancer cell line with high (DU145) and low (LNCaP) TF expression, peripheral blood mononuclear cells (PBMCs), and platelets. Co-incubation of DU145 EVs with PBMCs and platelets significantly increased EV-TF activity in conditioned medium and induced TF activity on monocytes. No such effects were seen in co-culture experiments with LNCaP EVs. In conclusion, the findings indicate that elevated EV-TF activity plays a role in the development of prostate-cancer-related DIC and may result from interactions between tumor-derived EVs, monocytes, and platelets.
引用
收藏
页数:12
相关论文
共 33 条
[1]   Platelet tissue factor is not expressed transiently after platelet activation [J].
Bouchard, Beth A. ;
Krudysz-Amblo, Jolanta ;
Butenas, Saulius .
BLOOD, 2012, 119 (18) :4338-4339
[2]   Tissue factor activity in whole blood [J].
Butenas, S ;
Bouchard, BA ;
Brummel-Ziedins, KE ;
Parhami-Seren, B ;
Mann, KG .
BLOOD, 2005, 105 (07) :2764-2770
[3]   P-SELECTIN INDUCES THE EXPRESSION OF TISSUE FACTOR ON MONOCYTES [J].
CELI, A ;
PELLEGRINI, G ;
LORENZET, R ;
DEBLASI, A ;
READY, N ;
FURIE, BC ;
FURIE, B .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (19) :8767-8771
[4]   C-REACTIVE PROTEIN INDUCES HUMAN PERIPHERAL-BLOOD MONOCYTES TO SYNTHESIZE TISSUE FACTOR [J].
CERMAK, J ;
KEY, NS ;
BACH, RR ;
BALLA, J ;
JACOB, HS ;
VERCELLOTTI, GM .
BLOOD, 1993, 82 (02) :513-520
[5]  
CHONG BH, 1994, BLOOD, V83, P1535
[6]  
COOPER DL, 1992, CANCER-AM CANCER SOC, V70, P656, DOI 10.1002/1097-0142(19920801)70:3<656::AID-CNCR2820700319>3.0.CO
[7]  
2-T
[8]   The Uptake of Extracellular Vesicles is Affected by the Differentiation Status of Myeloid Cells [J].
Czernek, L. ;
Chworos, A. ;
Duechler, M. .
SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 2015, 82 (06) :506-514
[9]  
Deutsch E, 1976, Prog Clin Biol Res, V6, P313
[10]   VASCULAR TOXICITY ASSOCIATED WITH ANTINEOPLASTIC AGENTS [J].
DOLL, DC ;
RINGENBERG, QS ;
YARBRO, JW .
JOURNAL OF CLINICAL ONCOLOGY, 1986, 4 (09) :1405-1417